×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Exchange
/
Drug Targets
🎯 Drug Targets
Browse 10 drug targets with druggability analysis, composite scores, and clinical context
10
Targets
0
High Druggability
0.60
Avg Score
15
Target Classes
Druggability Distribution
High:
0
Medium:
3
Low:
7
Unknown:
0
Avg druggability score:
0.405
Clinical Pipeline
Approved:
5
Phase III:
1
Phase II:
3
Phase I:
1
Preclinical:
0
Total compounds:
18
· Approved:
6
Search
Class
All Classes
Enzyme
(35)
Signaling Protein
(25)
Structural Protein
(17)
Protein
(16)
Gpcr
(13)
Ion Channel
(12)
Transcription Factor
(11)
Receptor
(11)
Ligand
(10)
Transporter
(8)
Epigenetic Regulator
(8)
Kinase
(7)
Protease
(4)
Other
(4)
Chaperone
(4)
Druggability
Low
(100)
Medium
(62)
High
(14)
Undruggable
(6)
other
(3)
Sort
Score
Druggability
Gene A-Z
Market Price
Filtered by: class=ligand — 10 results
IL1B
Interleukin-1 beta
Phase 4
Ligand
Medium Druggability
Score
0.73
Drug.
0.49
Safety
0.60
Drugs
2
Hyps
3
Papers
0
IL-1 receptor antagonist or neutralizing monoclonal antibody
APOE
Apolipoprotein E
Phase 2
Ligand
Medium Druggability
Score
0.64
Drug.
0.47
Safety
0.40
Drugs
4
Hyps
50
Papers
31
Protein-protein interaction modulator or lipid metabolism enhancer
ANGPT1
Angiopoietin-1
Phase 4
Ligand
Low Druggability
Score
0.63
Drug.
0.45
Safety
0.50
Drugs
1
Hyps
1
Papers
18
Protein therapeutics or small molecule mimetics activating Tie2 signaling
TGFB1
Transforming growth factor beta-1
Phase 3
Ligand
Low Druggability
Score
0.63
Drug.
0.44
Safety
0.30
Drugs
2
Hyps
3
Papers
18
Monoclonal antibodies neutralizing TGF-β1 or small molecule inhibitors of TGF-β signaling
IL10
Interleukin-10
Phase 2
Ligand
Low Druggability
Score
0.62
Drug.
0.36
Safety
0.30
Drugs
1
Hyps
3
Papers
0
Recombinant protein replacement or monoclonal antibody modulation
BDNF
Brain Derived Neurotrophic Factor
Phase 2
Ligand
Low Druggability
Score
0.59
Drug.
0.29
Safety
0.60
Drugs
1
Hyps
47
Papers
18
Protein replacement therapy or small molecule mimetic
NTN1
Netrin-1
Phase 1
Ligand
Low Druggability
Score
0.57
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
1
Papers
24
Modulation of axon guidance and neuronal survival pathways
HCRT
Hypocretin/Orexin
Phase 4
Ligand
Medium Druggability
Score
0.55
Drug.
0.46
Safety
0.60
Drugs
3
Hyps
3
Papers
31
Peptide hormone replacement or stabilization approaches
SST
Somatostatin
Phase 4
Ligand
Low Druggability
Score
0.54
Drug.
0.41
Safety
0.70
Drugs
2
Hyps
5
Papers
0
Somatostatin is a peptide neurotransmitter that modulates neuronal signaling by inhibiting hormone release and neuronal excitability, with emerging evidence suggesting its potential neuroprotective role in neurodegenerative processes through regulation of inflammatory responses and synaptic plasticity. In neurodegeneration contexts, SST receptors may serve as modulators of neuroinflammatory cascades and potentially mitigate progressive neuronal damage through receptor-mediated signaling mechanisms.
CRH
Corticotropin Releasing Hormone
Phase 4
Ligand
Low Druggability
Score
0.54
Drug.
0.34
Safety
0.60
Drugs
1
Hyps
1
Papers
18
CRH receptor antagonist blocking stress hormone signaling